Bruker

• 8-KDividend

  Filed Aug 14

  Board declares quarterly cash dividend payable Oct. 7, 2026 to shareholders of record Sept. 21

• 10-QQ2 FY2026Impairment / charge

  Filed Aug 5

  CST and BSB goodwill impairments overwhelmed stronger gross profit; the Q3 segment reorganization prompts another impairment review.

  • Revenue$838.5MYoY +5.2%
  • Net income−$52.0Mvs $7.6M year ago

• 8-KPositiveEarningsGuidance reaffirmedImpairment / charge

  Filed Aug 4

  BSI bookings strengthened as organic revenue growth resumed; a noncash goodwill impairment contributed to a GAAP operating loss.

• 8-KDividend

  Filed Jul 30

  Quarterly cash dividend declared on Series A mandatory convertible preferred stock, payable Sept. 1 to holders of record Aug. 15.

• 8-KShareholder vote

  Filed May 21

  Stockholders elected three Class II directors to three-year terms and ratified PricewaterhouseCoopers as FY2026 auditor.

• 8-KDividend

  Filed May 15

  Quarterly cash dividend declared for shareholders of record June 22, payable July 7, 2026.

• 10-QQ1 FY2026NegativeRestructuringImpairment / charge

  Filed May 7

  Tofwerk and currency masked falling organic sales as China and research demand weakened; NANO restructuring pressured margins.

  • Revenue$823.4MYoY +2.7%
  • Net income$14.4MYoY −17.2%

• 8-KNegativeEarningsGuidance reaffirmed

  Filed May 6

  U.S. academic weakness and tariffs pressured organic sales; BSI bookings strengthened, with organic growth expected to return in Q2.

• 8-KDividend

  Filed Apr 28

  Board declares quarterly cash dividend on Series A mandatory convertible preferred stock.

• 8-KLeadership change

  Filed Apr 10

  Falko Busse will step down as Bruker BioSpin President around May 1 and leave October 31, 2026, forfeiting unvested equity.

• 8-KLeadership change

  Filed Apr 1

  QIAGEN CEO Thierry L. Bernard joins the Board, expanding it to 12 directors.

• 10-KFY2025NegativeRestructuringImpairment / charge

  Filed Feb 27

  Weak BioSpin and NANO demand, tariffs and impairments overwhelmed CALID growth; Bruker is restructuring to restore margins.

  • Revenue$3.4BYoY +2.1%
  • Net income−$8.6Mvs $113.1M year ago

• 8-KLeadership change

  Filed Feb 20

  Cynthia M. Friend will not stand for re-election in 2026; Jack Phillips moves from Class III to Class II with Board service uninterrupted.

• 8-KEarningsNew guidanceRestructuringImpairment / charge

  Filed Feb 12

  Biopharma and industrial research recovered as semiconductor orders improved; management targets a return to organic growth by Q2 2026.

• 8-KPositiveEarningsNew guidance

  Filed Jan 12

  Scientific Instruments orders outpace sales; FY2026 outlook targets non-GAAP organic margin expansion on flat to low-single-digit organic revenue growth.

Coverage: 10-K filings filed since Feb 27, 2026; 10-Q since May 7, 2026; 8-K since Jan 12, 2026.

Request longer coverage

Company data: Wikidata Q431454